WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRTX

Based on 16 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc

Min Forecast
$405.00+3.64%
Avg Forecast
$489.19+25.19%
Max Forecast
$567.00+45.1%

Should I buy or sell VRTX stock?

Based on 16 analysts offering ratings for Vertex Pharmaceuticals Inc.

Buy
Strong Buy
7 analysts 43.75%
Buy
3 analysts 18.75%
Hold
6 analysts 37.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their VRTX stock forecasts and price targets.

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-06
lockedlocked$00.00+00.00%2025-08-06
lockedlocked$00.00+00.00%2025-08-06
lockedlocked$00.00+00.00%2025-08-05
lockedlocked$00.00+00.00%2025-08-05
RBC Capital
Bottom 5%
5
HoldMaintains$405.00+3.64%2025-08-05
UBS
Bottom 5%
5
Strong BuyMaintains$553.00+41.52%2025-08-05
BMO Capital
Bottom 13%
13
BuyMaintains$530.00+35.63%2025-08-05
Cantor Fitzgerald
Top 15%
86
Strong BuyMaintains$485.00+24.12%2025-08-05
Stifel Nicolaus
Bottom 4%
4
HoldMaintains$455.00+16.44%2025-08-05

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?

Company
N/A
Industry
127.2%
Market
-48.11%

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?

Company
N/A
Industry
47.5%

VRTX earnings per share forecast

What is VRTX's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$15.89+12.53%
Avg 2 year Forecast
$17.64+24.95%
Avg 3 year Forecast
$18.48+30.85%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$12.0B+4.86%
Avg 2 year Forecast
$13.0B+14.19%
Avg 3 year Forecast
$14.1B+23.1%
VRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
10.17%
Industry
5.42%
Market
15.25%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
7.2%
Industry
79.33%
Market
10.78%
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRTX$390.76$489.19+25.19%Buy
REGN$571.78$714.67+24.99%Buy
ALNY$458.28$422.91-7.72%Strong Buy
ARGX$656.89$780.30+18.79%Strong Buy
ONC$312.51$335.78+7.45%Strong Buy
View Top Biotech Stocks

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: VRTX) stock is to Buy VRTX stock.

Out of 16 analysts, 7 (43.75%) are recommending VRTX as a Strong Buy, 3 (18.75%) are recommending VRTX as a Buy, 6 (37.5%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What is VRTX's earnings growth forecast for 2025-2027?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual earnings growth rate of 10.17% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Vertex Pharmaceuticals's earnings in 2025 is $3,637,600,000.On average, 11 Wall Street analysts forecast VRTX's earnings for 2025 to be $4,073,816,693, with the lowest VRTX earnings forecast at $3,930,468,680, and the highest VRTX earnings forecast at $4,217,626,209. On average, 12 Wall Street analysts forecast VRTX's earnings for 2026 to be $4,523,372,060, with the lowest VRTX earnings forecast at $4,179,167,611, and the highest VRTX earnings forecast at $5,073,970,983.

In 2027, VRTX is forecast to generate $4,737,253,141 in earnings, with the lowest earnings forecast at $4,668,873,755 and the highest earnings forecast at $4,771,430,015.

What is VRTX's revenue growth forecast for 2025-2027?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 7.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.

Vertex Pharmaceuticals's revenue in 2025 is $11,418,800,000.On average, 12 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,070,007,553,588, with the lowest VRTX revenue forecast at $3,045,510,708,838, and the highest VRTX revenue forecast at $3,094,071,098,138. On average, 12 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,342,978,475,207, with the lowest VRTX revenue forecast at $3,137,529,313,482, and the highest VRTX revenue forecast at $3,619,159,151,386.

In 2027, VRTX is forecast to generate $3,603,957,236,907 in revenue, with the lowest revenue forecast at $3,367,101,502,388 and the highest revenue forecast at $4,101,660,717,503.

What is VRTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VRTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 47.5%.

What is VRTX's Price Target?

According to 16 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $489.19, with the highest VRTX stock price forecast at $567.00 and the lowest VRTX stock price forecast at $405.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could reach $489.19 by Aug 6, 2026. The average Vertex Pharmaceuticals stock price prediction forecasts a potential upside of 25.19% from the current VRTX share price of $390.76.

What is VRTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VRTX) Vertex Pharmaceuticals's current Earnings Per Share (EPS) is $14.12. On average, analysts forecast that VRTX's EPS will be $15.89 for 2025, with the lowest EPS forecast at $15.33, and the highest EPS forecast at $16.45. On average, analysts forecast that VRTX's EPS will be $17.64 for 2026, with the lowest EPS forecast at $16.30, and the highest EPS forecast at $19.79. In 2027, VRTX's EPS is forecast to hit $18.48 (min: $18.21, max: $18.61).

What is VRTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VRTX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.